查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1553590

肺腺癌治療市場規模、佔有率和趨勢分析報告：2024-2030 年按治療、最終用途、地區和細分市場進行的預測

Lung Adenocarcinoma Treatment Market Size, Share & Trends Analysis Report By Treatment (Chemotherapy, Immunotherapy), By End-use (Hospitals, Specialty Clinics), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

肺腺癌治療市場的成長與趨勢：

Grand View Research最新報告顯示，到2030年，全球肺腺癌治療市場規模預計將達到111.8億美元，預測期內複合年成長率為10.68%。

該市場為肺腺癌（非小細胞肺癌（NSCLC）的一種亞型）的管理和治療提供了廣泛的治療選擇、技術和服務。

某些地區吸煙率上升、空氣污染和職業危害等環境因素是市場成長的主要動力。隨著越來越多的人被診斷出患有肺腺癌，對有效治療方案的需求也在增加。

提高對肺癌症狀和危險因素的認知正在對市場產生重大影響。旨在教育人們戒菸和及早發現的公共衛生宣傳活動增加了出現症狀後立即尋求醫療照護的人數。

2023年10月，百時美施貴寶以總計48億美元收購Mirati，其中包括治療晚期非小細胞肺癌的KRASG12C抑制劑KRAZATI（adagrasib），以及附帶或有權利的股權價值58億美元。

肺腺癌治療市場報告亮點：

  • 以治療方法，化療在 2023 年佔據市場主導地位。隨著個人化醫療的出現，針對肺腺癌患者特定基因突變的標靶化療方案已被開發出來，進一步提高了治療效果和患者預後。
  • 以最終用途分類，醫院佔據市場主導地位，2023 年銷售佔有率最大，為 64.34%。全球肺腺癌盛行率不斷上升，導致住院需求增加，因為患者需要只能在醫院進行的複雜干預措施，例如化療、標靶治療和外科手術。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章肺腺癌治療市場變數、趨勢和範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 肺腺癌治療市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第 4 章 肺腺癌治療市場：按治療分類的估計和趨勢分析

  • 全球肺腺癌治療市場：治療儀表板
  • 全球肺腺癌治療市場：治療變異分析
  • 全球肺腺癌治療市場：按治療分類的收益
  • 化療
  • 標靶治療
  • 免疫療法
  • 放射治療
  • 其他

第5章肺腺癌治療市場：按最終用途分類的估計和趨勢分析

  • 全球肺腺癌治療市場：最終用途儀表板
  • 全球肺腺癌治療市場：最終用途變化分析
  • 全球肺腺癌治療市場：按最終用途分類的收益
  • 醫院
  • 專科診所
  • 其他

第6章肺腺癌治療市場：按治療和最終用途的區域估計和趨勢分析

  • 區域儀表板
  • 2018-2030年市場規模、預測趨勢分析：
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東/非洲

第7章 競爭格局

  • 公司/競爭對手分類
  • 供應商情況
    • 主要經銷商及通路夥伴名單
    • 2023年主要企業市場佔有率分析
    • Pfizer
    • AstraZeneca
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • Boehringer Ingelheim International GmbH
    • Novartis AG
    • Merck KGaA（EMD Serono）
    • AbbVie Inc.
    • Astellas Pharma Inc.
    • F. Hoffmann-La Roche
Product Code: GVR-4-68040-428-6

Lung Adenocarcinoma Treatment Market Growth & Trends:

The global lung adenocarcinoma treatment market size is anticipated to reach USD 11.18 billion by 2030 and is projected to grow at a CAGR of 10.68% during the forecast period, according to a new report by Grand View Research, Inc. This market offers a range of therapeutic options, technologies, and services aimed at managing and treating lung adenocarcinoma, which is a subtype of non-small cell lung cancer (NSCLC).

The rise in smoking rates in certain regions and environmental factors such as air pollution and occupational hazards are key growth drivers for market growth. As more individuals are diagnosed with lung adenocarcinoma, there is a corresponding demand for effective treatment options.

Increased awareness about lung cancer symptoms and risk factors has significantly influenced the market. Public health campaigns aimed at educating populations about smoking cessation and early detection led to more individuals seeking medical attention sooner after experiencing symptoms.

In October 2023, Bristol Myers Squibb acquired Mirati for USD 58.00 per share, totaling USD 4.8 billion in equity value, potentially rising to USD 5.8 billion with contingent value rights, including KRAZATI (adagrasib), a KRASG12C inhibitor for advanced non-small cell lung cancer.

Lung Adenocarcinoma Treatment Market Report Highlights:

  • On the basis of treatment, chemotherapy dominated the market in 2023. The advent of personalized medicine led to the development of targeted chemotherapy regimens tailored to specific genetic mutations found in lung adenocarcinoma patients, further enhancing treatment efficacy and patient outcomes.
  • On the basis of end use, hospitals dominated the market with the largest revenue share of 64.34% in 2023. The increasing prevalence of lung adenocarcinoma globally has led to a higher demand for hospitalization, as patients require complex interventions such as chemotherapy, targeted therapy, and surgical procedures that can only be performed in a hospital setting.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Treatment
    • 1.2.2. End Use
    • 1.2.3. Regional scope
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Treatment Outlook
    • 2.2.2. End Use Outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Lung Adenocarcinoma Treatment Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. The increasing incidence of lung cancer
      • 3.2.1.2. Advancements in targeted therapies and immunotherapies
      • 3.2.1.3. The growing emphasis on personalized medicine
      • 3.2.1.4. The rising demand for early detection and screening programs
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High cost of treatments
      • 3.2.2.2. Limited availability of skilled healthcare professionals
  • 3.3. Lung Adenocarcinoma Treatment Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Lung Adenocarcinoma Treatment Market: Treatments Estimates & Trend Analysis

  • 4.1. Global Lung Adenocarcinoma Treatment Market: Treatments Dashboard
  • 4.2. Global Lung Adenocarcinoma Treatment Market: Treatments Movement Analysis
  • 4.3. Global Lung Adenocarcinoma Treatment Market by Treatments, Revenue
  • 4.4. Chemotherapy
    • 4.4.1. Chemotherapy market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Targeted Therapy
    • 4.5.1. Targeted Therapy market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Immunotherapy
    • 4.6.1. Immunotherapy market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Radiation Therapy
    • 4.7.1. Radiation Therapy market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8. Other
    • 4.8.1. Other market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Lung Adenocarcinoma Treatment Market: End Use Estimates & Trend Analysis

  • 5.1. Global Lung Adenocarcinoma Treatment Market: End Use Dashboard
  • 5.2. Global Lung Adenocarcinoma Treatment Market: End Use Movement Analysis
  • 5.3. Global Lung Adenocarcinoma Treatment Market Estimates and Forecasts, By End Use, Revenue (USD Million)
  • 5.4. Hospitals
    • 5.4.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Specialty Clinics
    • 5.5.1. Specialty Clinics market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Other
    • 5.6.1. Other market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Lung Adenocarcinoma Treatment Market: Regional Estimates & Trend Analysis by Treatments, and End Use

  • 6.1. Regional Dashboard
  • 6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.3. North America
    • 6.3.1. U.S.
      • 6.3.1.1. Key country dynamics
      • 6.3.1.2. Regulatory framework/ reimbursement structure
      • 6.3.1.3. Competitive scenario
      • 6.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.2. Canada
      • 6.3.2.1. Key country dynamics
      • 6.3.2.2. Regulatory framework/ reimbursement structure
      • 6.3.2.3. Competitive scenario
      • 6.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.3. Mexico
      • 6.3.3.1. Key country dynamics
      • 6.3.3.2. Regulatory framework/ reimbursement structure
      • 6.3.3.3. Competitive scenario
      • 6.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Key country dynamics
      • 6.4.1.2. Regulatory framework/ reimbursement structure
      • 6.4.1.3. Competitive scenario
      • 6.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Germany
      • 6.4.2.1. Key country dynamics
      • 6.4.2.2. Regulatory framework/ reimbursement structure
      • 6.4.2.3. Competitive scenario
      • 6.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. France
      • 6.4.3.1. Key country dynamics
      • 6.4.3.2. Regulatory framework/ reimbursement structure
      • 6.4.3.3. Competitive scenario
      • 6.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.4. Italy
      • 6.4.4.1. Key country dynamics
      • 6.4.4.2. Regulatory framework/ reimbursement structure
      • 6.4.4.3. Competitive scenario
      • 6.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.5. Spain
      • 6.4.5.1. Key country dynamics
      • 6.4.5.2. Regulatory framework/ reimbursement structure
      • 6.4.5.3. Competitive scenario
      • 6.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.6. Norway
      • 6.4.6.1. Key country dynamics
      • 6.4.6.2. Regulatory framework/ reimbursement structure
      • 6.4.6.3. Competitive scenario
      • 6.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.7. Sweden
      • 6.4.7.1. Key country dynamics
      • 6.4.7.2. Regulatory framework/ reimbursement structure
      • 6.4.7.3. Competitive scenario
      • 6.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.8. Denmark
      • 6.4.8.1. Key country dynamics
      • 6.4.8.2. Regulatory framework/ reimbursement structure
      • 6.4.8.3. Competitive scenario
      • 6.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/ reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.2. China
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/ reimbursement structure
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.3. India
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework/ reimbursement structure
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.4. Australia
      • 6.5.4.1. Key country dynamics
      • 6.5.4.2. Regulatory framework/ reimbursement structure
      • 6.5.4.3. Competitive scenario
      • 6.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.5. South Korea
      • 6.5.5.1. Key country dynamics
      • 6.5.5.2. Regulatory framework/ reimbursement structure
      • 6.5.5.3. Competitive scenario
      • 6.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.6. Thailand
      • 6.5.6.1. Key country dynamics
      • 6.5.6.2. Regulatory framework/ reimbursement structure
      • 6.5.6.3. Competitive scenario
      • 6.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/ reimbursement structure
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.2. Argentina
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/ reimbursement structure
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. MEA
    • 6.7.1. South Africa
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/ reimbursement structure
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.2. Saudi Arabia
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/ reimbursement structure
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.3. UAE
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/ reimbursement structure
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.4. Kuwait
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/ reimbursement structure
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Company/Competition Categorization
  • 7.2. Vendor Landscape
    • 7.2.1. List of key distributors and channel partners
    • 7.2.2. Key company market share analysis, 2023
    • 7.2.3. Pfizer
      • 7.2.3.1. Company overview
      • 7.2.3.2. Financial performance
      • 7.2.3.3. Product benchmarking
      • 7.2.3.4. Strategic initiatives
    • 7.2.4. AstraZeneca
      • 7.2.4.1. Company overview
      • 7.2.4.2. Financial performance
      • 7.2.4.3. Product benchmarking
      • 7.2.4.4. Strategic initiatives
    • 7.2.5. Bristol-Myers Squibb Company
      • 7.2.5.1. Company overview
      • 7.2.5.2. Financial performance
      • 7.2.5.3. Product benchmarking
      • 7.2.5.4. Strategic initiatives
    • 7.2.6. Eli Lilly and Company
      • 7.2.6.1. Company overview
      • 7.2.6.2. Financial performance
      • 7.2.6.3. Product benchmarking
      • 7.2.6.4. Strategic initiatives
    • 7.2.7. Boehringer Ingelheim International GmbH
      • 7.2.7.1. Company overview
      • 7.2.7.2. Financial performance
      • 7.2.7.3. Product benchmarking
      • 7.2.7.4. Strategic initiatives
    • 7.2.8. Novartis AG
      • 7.2.8.1. Company overview
      • 7.2.8.2. Financial performance
      • 7.2.8.3. Product benchmarking
      • 7.2.8.4. Strategic initiatives
    • 7.2.9. Merck KGaA (EMD Serono)
      • 7.2.9.1. Company overview
      • 7.2.9.2. Financial performance
      • 7.2.9.3. Product benchmarking
      • 7.2.9.4. Strategic initiatives
    • 7.2.10. AbbVie Inc.
      • 7.2.10.1. Company overview
      • 7.2.10.2. Financial performance
      • 7.2.10.3. Product benchmarking
      • 7.2.10.4. Strategic initiatives
    • 7.2.11. Astellas Pharma Inc.
      • 7.2.11.1. Company overview
      • 7.2.11.2. Financial performance
      • 7.2.11.3. Product benchmarking
      • 7.2.11.4. Strategic initiatives
    • 7.2.12. F. Hoffmann-La Roche
      • 7.2.12.1. Company overview
      • 7.2.12.2. Financial performance
      • 7.2.12.3. Product benchmarking
      • 7.2.12.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 North America Lung adenocarcinoma treatment market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America Lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 4 North America Lung adenocarcinoma treatment market, by End Use, 2018 - 2030 (USD Million)
  • Table 5 U.S. Lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 6 U.S. Lung adenocarcinoma treatment market, by End Use, 2018 - 2030 (USD Million)
  • Table 7 Canada Lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 8 Canada Lung adenocarcinoma treatment market, by End Use, 2018 - 2030 (USD Million)
  • Table 9 Mexico Lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 10 Mexico Lung adenocarcinoma treatment market, by End Use, 2018 - 2030 (USD Million)
  • Table 11 Europe Lung adenocarcinoma treatment market, by region, 2018 - 2030 (USD Million)
  • Table 12 Europe Lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 13 Europe Lung adenocarcinoma treatment market, by End Use, 2018 - 2030 (USD Million)
  • Table 14 Germany Lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 15 Germany Lung adenocarcinoma treatment market, by End Use, 2018 - 2030 (USD Million)
  • Table 16 UK Lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 17 UK Lung adenocarcinoma treatment market, by End Use, 2018 - 2030 (USD Million)
  • Table 18 France Lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 19 France Lung adenocarcinoma treatment market, by End Use, 2018 - 2030 (USD Million)
  • Table 20 Italy Lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 21 Italy Lung adenocarcinoma treatment market, by End Use, 2018 - 2030 (USD Million)
  • Table 22 Spain Lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 23 Spain Lung adenocarcinoma treatment market, by End Use, 2018 - 2030 (USD Million)
  • Table 24 Denmark Lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 25 Denmark Lung adenocarcinoma treatment market, by End Use, 2018 - 2030 (USD Million)
  • Table 26 Sweden Lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 27 Sweden Lung adenocarcinoma treatment market, by End Use, 2018 - 2030 (USD Million)
  • Table 28 Norway Lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 29 Norway Lung adenocarcinoma treatment market, by End Use, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific Lung adenocarcinoma treatment market, by region, 2018 - 2030 (USD Million)
  • Table 31 Asia Pacific Lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 32 Asia Pacific Lung adenocarcinoma treatment market, by End Use, 2018 - 2030 (USD Million)
  • Table 33 China Lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 34 China Lung adenocarcinoma treatment market, by End Use, 2018 - 2030 (USD Million)
  • Table 35 Japan Lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 36 Japan Lung adenocarcinoma treatment market, by End Use, 2018 - 2030 (USD Million)
  • Table 37 India Lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 38 India Lung adenocarcinoma treatment market, by End Use, 2018 - 2030 (USD Million)
  • Table 39 South Korea Lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 40 South Korea Lung adenocarcinoma treatment market, by End Use, 2018 - 2030 (USD Million)
  • Table 41 Australia Lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 42 Australia Lung adenocarcinoma treatment market, by End Use, 2018 - 2030 (USD Million)
  • Table 43 Thailand Lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 44 Thailand Lung adenocarcinoma treatment market, by End Use, 2018 - 2030 (USD Million)
  • Table 45 Latin America Lung adenocarcinoma treatment market, by region, 2018 - 2030 (USD Million)
  • Table 46 Latin America Lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 47 Latin America Lung adenocarcinoma treatment market, by End Use, 2018 - 2030 (USD Million)
  • Table 48 Brazil Lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 49 Brazil Lung adenocarcinoma treatment market, by End Use, 2018 - 2030 (USD Million)
  • Table 50 Argentina Lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 51 Argentina Lung adenocarcinoma treatment market, by End Use, 2018 - 2030 (USD Million)
  • Table 52 MEA Lung adenocarcinoma treatment market, by region, 2018 - 2030 (USD Million)
  • Table 53 MEA Lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 54 MEA Lung adenocarcinoma treatment market, by End Use, 2018 - 2030 (USD Million)
  • Table 55 South Africa Lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 56 South Africa Lung adenocarcinoma treatment market, by End Use, 2018 - 2030 (USD Million)
  • Table 57 Saudi Arabia Lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 58 Saudi Arabia Lung adenocarcinoma treatment market, by End Use, 2018 - 2030 (USD Million)
  • Table 59 UAE Lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 60 UAE Lung adenocarcinoma treatment market, by End Use, 2018 - 2030 (USD Million)
  • Table 61 Kuwait Lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 62 Kuwait Lung adenocarcinoma treatment market, by End Use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Market research approaches
  • Fig. 4 QFD modeling for market share assessment
  • Fig. 5 Market formulation & validation
  • Fig. 6 Lung adenocarcinoma treatment market: market outlook
  • Fig. 7 Lung adenocarcinoma treatment competitive insights
  • Fig. 8 Parent market outlook
  • Fig. 9 Related/ancillary market outlook
  • Fig. 10 Lung adenocarcinoma treatment market driver impact
  • Fig. 11 Lung adenocarcinoma treatment market restraint impact
  • Fig. 12 Lung adenocarcinoma treatment market: Treatment movement analysis
  • Fig. 13 Lung adenocarcinoma treatment market: Treatment outlook and key takeaways
  • Fig. 14 Chemotherapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 15 Targeted therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 16 Immunotherapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 17 Radiation therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 18 Other market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 Lung adenocarcinoma treatment market: End Use movement analysis
  • Fig. 20 Lung adenocarcinoma treatment market: End Use outlook and key takeaways
  • Fig. 21 Hospitals market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Specialty clinics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Other market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Global Lung adenocarcinoma treatment market: Regional movement analysis
  • Fig. 25 Global Lung adenocarcinoma treatment market: Regional outlook and key takeaways
  • Fig. 26 Global Lung adenocarcinoma treatment market share and leading players
  • Fig. 27 North America, by country
  • Fig. 28 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 U.S. key country dynamics
  • Fig. 30 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Canada key country dynamics
  • Fig. 32 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Mexico key country dynamics
  • Fig. 34 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 UK key country dynamics
  • Fig. 37 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Germany key country dynamics
  • Fig. 39 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 France key country dynamics
  • Fig. 41 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Italy key country dynamics
  • Fig. 43 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Spain key country dynamics
  • Fig. 45 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Denmark key country dynamics
  • Fig. 47 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Sweden key country dynamics
  • Fig. 49 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Norway key country dynamics
  • Fig. 51 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 China key country dynamics
  • Fig. 54 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Japan key country dynamics
  • Fig. 56 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 India key country dynamics
  • Fig. 58 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Thailand key country dynamics
  • Fig. 60 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 South Korea key country dynamics
  • Fig. 62 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Australia key country dynamics
  • Fig. 64 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 Brazil key country dynamics
  • Fig. 67 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Argentina key country dynamics
  • Fig. 69 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 South Africa key country dynamics
  • Fig. 72 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 Saudi Arabia key country dynamics
  • Fig. 74 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 75 UAE key country dynamics
  • Fig. 76 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 77 Kuwait key country dynamics
  • Fig. 78 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 Market share of key market players- Lung adenocarcinoma treatment market